Cargando…
Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis
Resminostat, a novel class I, IIb, and IV histone deacetylase inhibitor, was studied in advanced hepatocellular carcinoma (HCC) patients after relapse to sorafenib (SHELTER study). In this phase I/II clinical trial, combination of sorafenib and resminostat was safe and showed early signs of efficacy...
Autores principales: | Soukupova, Jitka, Bertran, Esther, Peñuelas-Haro, Irene, Urdiroz-Urricelqui, Uxue, Borgman, Matthias, Kohlhof, Hella, Fabregat, Isabel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746389/ https://www.ncbi.nlm.nih.gov/pubmed/29299154 http://dx.doi.org/10.18632/oncotarget.22775 |
Ejemplares similares
-
Epithelial–Mesenchymal Transition (EMT) Induced by TGF-β in Hepatocellular Carcinoma Cells Reprograms Lipid Metabolism
por: Soukupova, Jitka, et al.
Publicado: (2021) -
The therapeutic properties of resminostat for hepatocellular carcinoma
por: Zhao, Jun, et al.
Publicado: (2018) -
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma
por: Streubel, Gundula, et al.
Publicado: (2021) -
Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism
por: Soukupova, Jitka, et al.
Publicado: (2017) -
The TGF-β/NADPH Oxidases Axis in the Regulation of Liver Cell Biology in Health and Disease
por: Herranz-Itúrbide, Macarena, et al.
Publicado: (2021)